Here, we detail exciting advances of leading pan-cancer theranostic agents targeting fibroblast activation protein (FAP), hypoxia, gastrin-releasing peptide receptors (GRPrs), and integrins, respectively, which offer the promise of significantly impacting cancer imaging and therapy in the coming years. This evidence concerns the gene GRPR and cancer.